Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2/3 1

Status

Terminated 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Urinary Bladder Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 4

Interventions

apaziquone 4Mitomycin 3viscum album peptide 1valrubicin 1pembrolizumab 1linrodostat 1enzalutamide 1enfortumab vedotin 1avelumab 1Sugars 1Standard of Care 1Polysorbates 1Pentosan Sulfuric Polyester 1Nivolumab 1Gemcitabine 1DDMS 1Capsules 1Bevacizumab 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Non-Muscle Invasive Bladder Neoplasms × apaziquone × Clear all
NCT02563561 2021-10-27

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
62 enrolled 10 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01469221 2017-12-15

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
47 enrolled 11 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01475266 2017-03-29

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Nippon Kayaku Co., Ltd.

Phase 2/3 Terminated
51 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01410565 2016-12-13

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
66 enrolled 12 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡